Liraglutide
Liraglutide, a peptide. GLP-1(7-37) analog with Arg-34 and palmitoyl (C-16) on Lys-26 via γGlu linker → albumin binding → 13 h t½ (vs.… Subcutaneous half-life 13 h.
GLP-1(7-37) analog with Arg-34 and palmitoyl (C-16) on Lys-26 via γGlu linker → albumin binding → 13 h t½ (vs. native GLP-1's 1.5 min). Daily SC dosing. Predated semaglutide; replaced for most indications by weekly agents.
PK: Agersø 2002 (PMID:11935150), 30 healthy men, SC, verbatim "the half-life of NN2211 was found to be 12.6 +/- 1.1 h" — a point estimate replacing the stored 13 h, which was the midpoint of the previous citation's "11-15 h" range. NN2211 is liraglutide's pre-approval code name. V 7 L dropped: it was the registry-wide plasma-volume default and is wrong in direction, but the approval document's ~13 L could not be substituted because no indexed abstract states a liraglutide volume — Watson 2010 (PMID:20133507) describes the model structure and publishes no parameters. ka 0.1 /h and F 0.55 dropped for the same reason. This class keeps its parameter estimates in labels and full-text tables rather than abstracts.
Pharmacokinetics
- Subcutaneous — t½ 12.6 h
Sources: PMID:31031702, PMID:11935150